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Abstract
Obesity is strongly associated with the insulin resistance development and is 
an integral pathogenic part of the metabolic syndrome, type 2 diabetes, athero-
sclerosis, and other comorbid pathologies. It is well known that the obesity causes 
the disorders in adipose tissue endocrine and metabolic activity, which results 
in the activation of free radical processes. The administration of natural origin 
substances with antioxidant properties could be a promising direction for obesity 
and overweight correction. The objective of the current study was to evaluate 
the usefulness of natural origin active substances with antioxidant properties’ 
administration under the obesity and comorbid disorder treatment. This chapter 
presents the results of experimental studies that proved the usefulness of phenolic 
compounds from apple food concentrate (Malus domestica L.) and dry bilberry 
extract (Vaccinium myrtillus L.) application under experimental metabolic 
syndrome, insulin resistance syndrome, and type 2 diabetes mellitus, which 
are extremely associated with obesity. It has been found that due to expressive 
antioxidant activity, these compounds exhibit the high efficiency in carbohydrate 
metabolism disorders’ correction (in cases of metabolic syndrome and type 2 dia-
betes), lipids metabolism disorders’ correction (in case of metabolic syndrome), 
preventing of endothelial dysfunction under experimental insulin resistance, 
and normalization of antioxidant status in the liver (under experimental type 2 
diabetes mellitus).
Keywords: obesity, apple polyphenol extract, blueberry dry extract,  
metabolic syndrome, insulin resistance, antioxidant activity, diabetes mellitus
1. Introduction
According to clinical and epidemiological studies, obesity refers to diseases 
with high medical and social significance and has a pandemic rate of expansion. 
Obesity is a component of the multimorbid disease pathogenesis, in particular of 
metabolic syndrome (MS), type 2 diabetes mellitus (DT2), also it is a predictor of 
atherosclerosis and cardiovascular complications [1]. It is known that an imbalance 
of antioxidant-prooxidant factors (with a predominance of prooxidants) is associ-
ated with obesity development due to pathological changes in metabolic activity of 
the adipose tissue [2].
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The reactive oxygen species (ROS) production is primarily caused by the 
lipid accumulation, so it results in NADPH-oxidase excessive expression with the 
simultaneous decrease in the activity of antioxidant enzymes and nonenzyme 
antioxidants. Carbohydrate metabolism disorders lead to the activation of glucose 
metabolism polyol pathway and to protein pathological glycosylation along with 
metabolic end products accumulation. Oxidative stress leads to adipokines produc-
tion dysregulation, in particular, adiponectin, plasminogen activator inhibitor-1, 
interleukin-6, and monocyte chemotactic factor. It plays a leading role in the 
involvement of other metabolic pathways to the pathological process and main 
disease pathogenesis complications [3, 4].
Free radical upbuilding is a major event involved in vascular endothelium 
damaging as a trigger mechanism for the endothelial dysfunction (ED) and cardio-
vascular complications development related to obesity and MS. As is well known, 
just cardiovascular events determine high premature mortality rates of these patient 
categories. In addition, the pathological changes of the antioxidant-prooxidant bal-
ance leads to the low-density lipoproteins (LDL) oxidative modification, which are 
the leading link to the proatherogenic process essential for obesity and associated 
pathologies [5].
The metabolic disorders’ pathogenetic aspects that appear under MS are mainly 
based on the free radical oxidation (FRO) processes activation. Concerning the 
above mentioned, the antioxidant use is promising treatment strategy for correc-
tion of pathological states that developed under the insulin resistance (IR) [6].
Common therapeutic pharmacological correction strategies for obesity-
associated diseases include the synthetic drug use, which are powerful microsomal 
oxidation processes activators that, in turn, initiates the FRO intensification and 
increases the ROS production. Recently, there is an increasing interest to the 
development and research of natural origin substances that can be used at the 
complex obesity-associated pathologies treatment. Plant polyphenols with expres-
sive antioxidant activity can potentially demonstrate a therapeutic effect under 
MS pathogenetic manifestations and related comorbidities, including ED [7]. The 
mentioned metabolic disorders are mediated by chronic subclinical inflammatory 
process, which is intermediated by the adipocytes production of various active 
molecules, which, as usual, are factors of high cardiometabolic risk. That is why the 
evaluation of usefulness of natural origin substances with antioxidant properties 
administration under the obesity treatment was the aim of our work.
2.  The preclinical study of phenolic compounds from apple food concentrate 
under experimental metabolic syndrome and insulin resistance syndrome
2.1  The effect of phenolic compounds from apple food concentrate on indices of 
carbohydrate and lipid metabolism under experimental metabolic syndrome
2.1.1 Materials and methods
Taking into account the significant role of reactive oxygen species (ROS) in the 
pathogenesis of obesity and associated diseases, the nutritional apple polyphenol 
food concentrate (APFC) investigation is seemed to be reasonable. Examined con-
centrate is rich in phenolic substances that reveal expressive antioxidant properties 
under the experimental MS. The investigated food concentrate was developed at 
the Pharmacognosy Department of the National University of Pharmacy under the 
supervision of Pharm. D. Koshoviy O.M. The food concentrate biological activity is 
primary caused by gallic acid, caffeic acid, chlorogenic acid, ursolic acid, quercetin, 
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epicatechin, leuco-anthocyanins, and ascorbic acid. The purified compound epigal-
locatechin gallate (EGCG, Sigma-Aldrich) was selected as a reference preparation 
because of its proven strong antioxidant properties.
Experimental MS was modeled in Syrian golden hamsters (males, 20 weeks old) 
that were fed high-calorie diet enriched by energy sources (containing 29% fat, 
mostly saturated lipids) and fructose (1 g/100 g of body weight per day per) (as 
aqueous solution) for 5 weeks. Animals of intact control group were fed a standard 
balanced diet for hamsters during the experiment [8]. Basal blood glucose concen-
tration in animal serum was determined using One touch ultra-easy glucose meter 
based on glucose oxidase method (manufactured by LifeScan, Johnson & Johnson, 
USA) [9]. The basal blood level of immunoreactive insulin (IRI) was determined 
using in vitro radioimmunoassay by the standard set of reagents (manufactured by 
Immundiagnostik, Germany). Insulin resistance index (HOMA-IR) was calculated 
from animal blood values of basal glucose and IRI indicators using Homeоstasis 
Model Assessment algorithm (НОМА) [10]. The content of triacylglycerols (TAG) 
in serum and in the liver homogenate was determined using the standard set of 
reagents “KONE” (Finland) based on glycerol oxidation method. Determination 
of the free fatty acids (FFA) concentration in serum was carried out using a set of 
reagents produced by Kamiya biomedical company (USA). The concentration of 
total lipids was determined in liver homogenate using the standard kit produced by 
Eagle Diagnostics (USA) based on the reaction with a vanillin reagent. The content 
of high-density lipoproteins (HDL) and apo-B-containing lipoproteins (sum of 
low-density lipoproteins and very low-density lipoproteins—apoB-L) were deter-
mined in blood serum using turbidimetric method [11, 12].
Experimental animals were administered APFC for 2 weeks (since third week of 
pathology simulation) using a special iron catheter for intragastric administering. The 
dose of APFC was calculated as total content of polyphenols—9 mg/100 g of body 
weight (prophylactic treatment). The dose of reference preparation epigallocatechin 
gallate—EGCG (produced by Sigma-Aldrich, Germany) was 3 mg/100 g of body 
weight. Daily animal equivalent doses (AED) were calculated according to the latest 
recommendations for preclinical studies, taking into account the average daily dose for 
humans and interspecies difference in body weight and body surface area [13].
The results were statistically processed using the 4Pl statistical logistic method 
with free internet service of MyAssays® and nonparametric analysis methods 
(Mann-Whitney U-Test) with the standard software package STATISTICA 7.0 [14].
2.1.2 Results
The carried studies indicated expressive corrective effect of the test concentrate 
and EGCG on the markers of carbohydrate and lipid metabolism in the Syrian 
hamsters with experimental MS, which, however, had rather significant group 
differences (Tables 1–3).
Under the experimental conditions, APFC usage led to the normalization of 
glucose and IRI indices, in which content was significantly reduced by 19.5 and 
21.02% respectively in comparison with animals of the model pathology group. The 
IR index significant reduction by 24.18% was a confirmation of the studied food 
concentrate therapeutic effect (Table 1).
EGCG also significantly decreased glucose and IRI levels by 10.9 and 10.1%, 
respectively, compared to animals with an experimental MS; index of IR also pro-
portionally decreased (by 11.93%). It should be noted that the EGCG therapeutic 
effect was not so pronounced as after the apple concentrate of phenolic compounds 
administration. We suppose that it was mediated by complex multivector biologi-
cally active compounds effect in concentrate content.
Antioxidants
4
Normalization in lipid metabolism disturbances was observed under the influ-
ence of the APFC as well as EGCG administration, that was confirmed by the labora-
tory indices favorable dynamics in both serum and liver of animals (Tables 2 and 3). 
At the same time, a more pronounced effect was found in group of animals, which 
were administered with the apple concentrate.
Thereby, it was determined that in animals administered with the test concen-
trate, the content of FFA and TAG decreased, respectively, by 29.5 and 29.1%, com-
pared with those in the model pathology group. Additionally, it was demonstrated 
Parameters Intact control Model pathology APFC + model 
pathology
EGCG + model 
pathology
TL (mg/g) 108.25 ± 2.16 132.55 ± 2.35* 117.43 ± 1.86** 125.45 ± 1.67**
TAG (mg/g) 12.32 ± 0.75 14.24 ± 0.37* 13.18 ± 0.35** 13.47 ± 0.15**
n, number of animals in a group.*Variation is statistically significant in comparison with intact control group indices 
(р ≤ 0.001).
**Variation is statistically significant in comparison with model pathology group indices (р ≤ 0.001).
Table 3. 
The effect of apple food concentrate of phenolic compounds and epigallocatechin gallate on lipid metabolism 
parameters in hamster’s liver in experimental metabolic syndrome, n = 10.
Parameters Intact control Model pathology APFC + model 
pathology
EGCG + model 
pathology
Glucose 
(mmol/l)
5.800 ± 0.440 11.200 ± 0.390* 9.021 ± 0.450** 9.983 ± 0.565**
IRI (pmol/l) 92.500 ± 2.305 138.280 ± 2.406* 109.220 ± 2.380 124.35 ± 2.250**
Index ІR 
(HOMA-IR)
1.78 3.02* 2.29** 2.66**
n, number of animals in a group.*Variation is statistically significant in comparison with intact control group indices 
(р ≤ 0.001).
**Variation is statistically significant in comparison with model pathology group indices (р ≤ 0.001).
Table 1. 
The effect of apple phenolic compounds food concentrate and epigallocatechin gallate on carbohydrate 
metabolism indices under experimental metabolic syndrome, n = 10.
Parameters Intact control Model pathology APFC + model 
pathology
EGCG + model 
pathology
TAG 
(mmol/l)
1.950 ± 0.055 3.680 ± 0.146* 2.610 ± 0.017** 2.970 ± 0.012
FFA 
(mmol/l)
0.450 ± 0.020 1.438 ± 0.023* 1.015 ± 0.150** 1.109 ± 0.045
apoB-LP 
(mg/ml)
4.72 ± 0.23 6.68 ± 0.15* 5.09 ± 0.13** 5.44 ± 0.14
HDL (mg/
ml)
1.11 ± 0.05 0.98 ± 0.07* 1.08 ± 0.02** 1.01 ± 0.03
n, number of animals in a group.*Variation is statistically significant in comparison with intact control group indices 
(р ≤ 0.001).
**Variation is statistically significant in comparison with model pathology group indices (р ≤ 0.001).
Table 2. 
The effect of apple phenolic compounds food concentrate and epigallocatechin gallate on lipid metabolism 
indices in hamster’s blood serum under experimental metabolic syndrome, n = 10.
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with more favorable lipoprotein fractions ratio in this group of animals treated by 
APFC. Thus, the content of the atherogenic fraction apoB-LP decreased (by 23.9%), 
while the level of antiatherogenic HDL was increased (content did not significantly 
differ from the same index in healthy animals), which indicates a reduction in the 
risk of proatherogenic changes and atherosclerosis development (Table 2).
The same tendency was observed under EGCG administration—the significant 
correction as for lipid metabolism pathological changes under experimental MS, which 
was demonstrated via decrease in TAG and FFA content by 19.3 and 22.9% respec-
tively. In addition, under the EGCG action, the level of apoB-LP decreased (by 18.6%) 
and level of HDL slightly increased (by 3.06%), which is the evidence of MS-specific 
proatherogenic change reduction. However, the EGCG therapeutic effect was not so 
pronounced compared to the apple food concentrate of phenolic compounds.
Considering the fact that the studied food concentrate and EGCG showed 
pronounced corrective therapeutic effect as for pathological changes in blood lipid 
metabolism markers, it was appeared expedient to investigate the effect of these 
compounds on the lipid metabolism indices in the liver tissue.
There was a significant increase in the TL and TAG content in the liver in 
animals with a model pathology (in 1.22 and 1.16 times, respectively, in comparison 
with intact hamsters), which indicated the steatosis precondition formation, and 
primary was due to the lipid intensive flow from the bloodstream (Table 3).
The APFC administration caused substantial correction of the TL and TAG con-
tent in the liver, which did not significantly differ from the same indices in healthy 
animals (Table 3). This is a confirmation of the APFC beneficial effects as for pre-
venting the fatty liver disease development, which is an MS pathogenesis integral 
component. This effect was probably mediated by lipid flow inhibition from the 
blood to the liver under the APFC action, which was evidenced by a decrease in the 
blood content of these compounds (Table 2).
The EGCG administration to animals with experimental MS also was accom-
panied with a significant decrease in the TL and TAG content in the liver tissue by 
5.4 and 5.5%, respectively, indicating the ability of the test compounds to prevent 
the steatosis development under the MS. It should be noted that the TL level under 
EGCG administration was significantly higher than under APFC administration, in 
which prevention indicates about a less significant effect on liver fatty degeneration 
under experimental pathology. This dynamics is also a reason for EGCG’s less effect 
on the pathological change correction in lipid metabolism in animals` blood specific 
to MS and for significantly higher lipid flow from the blood stream.
2.1.3 Discussion
The APFC therapeutic effectiveness is the result of the constituent substances 
complex synergistic effect that mediates various types of biological activity, in 
particular, a powerful antioxidant effect, the normalization of energy homeostasis 
and lipid metabolism.
It is well known that gallic acid, which amount is the main part of test concentrate 
quantitative content, has an ability to regulate body weight and glucose homeostasis 
via the way of AMP-activated protein kinase (AMPK) upregulation and modulation of 
mitochondrial functions through the stimulation of a gamma receptor coactivator-1α, 
which activates by peroxisomal proliferator (PGC1α). It is assumed that the main 
molecular mechanism of gallic acid action is the effect on the AMRK/Sirt1/PGC1α sig-
naling pathway. In addition, gallic acid significantly improved homeostasis of glucose 
and insulin by the activation of AMPK (in the liver, muscle, and brown fat tissue) and 
the gene expression of uncoupling protein-1, which in general was manifested by an 
increase in energy expenditure and thermogenesis intensification without significant 
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effect on appetite. There is an evidence that gallic acid inhibits the gene expression of 
gluconeogenesis key enzymes and as a result makes a significant impact on the blood 
glucose level and downregulates the FFA content that was registered in our experi-
ments. In general, these data show the gallic acid beneficial effect on energy homeosta-
sis, making its usage sensible in treatment of IR and associated diseases [15–18].
Several studies show that another component of concentrate—quercetin—has 
therapeutic effect under MS. Quercetin manifests itself in improved insulin tissue 
sensitivity and in glucose level reduction that can be explained by α-glucosidase 
activity inhibition and stimulation of glucose absorption by skeletal muscle and 
liver cells [19]. Glucose is actively involved in glycolysis (due to increased activity of 
enzymes hexokinase and pyruvate kinase) and incorporated for glycogen synthesis 
in skeletal muscle and liver. In addition, quercetin corrects pathological changes in 
the cortisol and sex steroids content, counteracts the adipose tissue metabolic activ-
ity disorders, and normalizes cytokine profile under MS. The quercetin multivec-
tor effect leads to the normalization of carbohydrate and lipid metabolism, and 
reduced metabolic disorders caused by IR [20–23].
Ursolic acid in in vivo experiments in mice with simulated IR led to the 
inhibition of atherosclerotic plaque formation and systolic pressure reduction; 
however, mechanisms of these effects developing have not studied yet [24, 25]. 
Caffeic, chlorogenic, and ascorbic acids are powerful antioxidants that suppress 
the formation of free radicals, and ROS and strongly reduce the effects of oxida-
tive stress, which is an MS pathogenetic component. In addition, phenolic acids 
inhibit the activity of α-glucosidase and sodium glucose transporter (SGLT1) 
[26, 27]. Leucoanthocyanins are able to induce autophosphorylation of the 
insulin receptor, resulting in improved insulin signaling and increased affinity of 
cells to its action [28].
Thus, the APFC compounds administration under experimental MS signifi-
cantly prevented an increase in glucose and IRI, corrected the manifestations of IR, 
decreased the content of FFA and TAG, probably due to the insulin counteraction 
on lipolysis and the modulation of the FFA metabolism under the effect of phenolic 
compounds, which reduced the flow of lipids to the liver (confirmed by a decrease 
in TL and TAG content in the animals’ liver), normalized the lipoprotein blood 
spectrum (confirmed by a decrease in apo-LP and increased HDL contents), and 
improved the oxidative state in the liver. The pronounced therapeutic effect of 
the APFC could be mediated by the complex synergistic antioxidant effect of the 
constituent components—gallic, caffeic, chlorogenic and ursolic acids, quercetin, 
leucoanthocyanin, and ascorbic acid.
In general, observed changes indicate the ability of the studied concentrate to 
prevent the induction of proatherogenic disorders and the MS negative influence, 
such as the atherosclerosis development. These harmful factors are the main cause 
of the cardiovascular diseases development and their complications in patients with 
metabolic disorders [29].
According to the literature data, the mechanism of EGCG usage under the 
experimental MS is mediated by the effect on cellular mechanisms of glucose trans-
porters translocation stimulation, in particular GLUT4 (mainly due to activation of 
AMPC and/or phosphoinositide-3-kinase), which is manifested by a hyperglycemia 
reduction due to increased glucose transport in cells of fat and muscle tissue. The 
activation of AMPK also correlates with a decrease in the accumulation of lipids in 
the liver. As for EGCG, there is also the ability to induce the activity of the glyco-
genesis enzymes (liver glucokinase) and suppress the expression of enzymes of 
gluconeogenesis. EGCG inhibits the activity of α-glucosidase to a lesser extent than 
chlorogenic, gallic, and caffeic acids, and it is due to a smaller length of the hydro-
carbon chain of the polyphenolic molecule [7, 30].
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Thus, EGCG in the experimental MS showed a therapeutic effect, which was 
mainly due to the normalization of glucose metabolism and inhibition of lipid accu-
mulation in the liver, but anyway, the therapeutic effect of apple phenolic compounds 
food concentrate was more expressive.
2.2  The effect of apple polyphenolic food concentrate on the endothelial function 
under experimental insulin resistance
2.2.1 Materials and methods
The complications of cardiovascular system disorders’ development are specific 
to the diseases associated with obesity and IR syndrome. The main pathogenetic 
component of cardiovascular pathologies is the progression of ED. This fact has been 
proved in our studies and was corresponded with the literature data. Concerning the 
glycemic profile positive changes under the influence of the studied APFC and EGCG, 
it was decided to investigate these compounds effect on the endothelium functional 
state under the experimental IR (Tables 4 and 5).
A balance between the content of vasoconstrictor and vasodilator substances 
play the key role in vascular tone regulation, progression and prognosis as for the 
course of endothelial dysfunction (ED) [5]. The IR syndrome was modeled on male 
Wistar rats weighing 160–200 g, 3 months of age by continuous intraperitoneally 
Experimental groups Parameters
ЕТ-1 (pg/ml) S-NO (mmol/l) ЕТ-1/S-NO
Intact control 2.29 ± 0.14 0.49 ± 0.03 4.67 ± 0.13
Model pathology 5.91 ± 0.23* 0.15 ± 0.04* 39.4 ± 1.05*
APFC + model pathology 3.60 ± 0.15** 0.32 ± 0.04** 11.25 ± 1.04**
EGCG + model pathology 3.88 ± 0.10** 0.26 ± 0.02** 14.92 ± 1.01**
n, number of animals in a group.*Variation is statistically significant in comparison with intact control group indices 
(р ≤ 0.001).
**Variation is statistically significant in comparison with model pathology group indices (р ≤ 0.001).
Table 5. 
The effect of examined compounds on rat’s specific markers of endothelial function underexperimental insulin 
resistance (the tenth week of experiment), n = 10.
Experimental groups Parameters
NO2
− + NO3
− 
(mmol/l)
Arginine (mmol/l) Citrulline (mmol/l)
Intact control 122.20 ± 1.23 64.40 ± 0.65 41.30 ± 1.05
Model pathology 164.50 ± 1.15* 42.80 ± 0.43* 54.50 ± 1.21*
APFC + model pathology 125.82 ± 1.78** 69.50 ± 0.75** 43.39 ± 1.25**
EGCG + model pathology 136.85 ± 2.02**, # 58.25 ± 0.67**,# 46.13 ± 1.43**,#
n, number of animals in a group.*Variation is statistically significant in comparison with intact control group indices 
(р ≤ 0.001).
**Variation is statistically significant in comparison with model pathology group indices (р ≤ 0.001).
#Variation is statistically significant in comparison with indices of animals that were on apple food concentrate of 
phenolic compounds (р ≤ 0.001).
Table 4. 
The effect of test compounds on rat’s NO-synthase system markers under experimental insulin resistance (the 
fifth week of experiment), n = 10.
Antioxidants
8
dexamethasone administration in low doses (15 μg/kg), while feeding high calorie 
diet (containing 29% fat—mostly saturated lipids) enriched with fructose (daily 
1/100 g of body weight as an aqueous solution) for 5 or 10 weeks [31].
Determination of arginine content in blood serum was carried out using a 
photometric method based on the reaction with α-naphthol and hypobromite 
reagent. The citrulline content was determined by reaction with diacetyl monox-
ime in strongly acidic conditions [32]. The content of nitrites and nitrates in 
blood serum was determined by spectrophotometric method using Griess test. 
The method is based on the determination of the total level of nitrogen (II) oxide 
metabolites (blood serum is incubated with a Griess reagent without vanadium 
chloride (III), determined spectrophotometrically). To obtain the value of 
the content of nitrates, it has to subtract concentrations of nitrite ions from 
the obtained value (the blood serum was incubated with a Griess reagent and 
vanadium chloride (III), spectrophotometrically determined) [33]. The serum 
endothelin-1 (ET-1) content was measured by the immune enzyme method using 
a standard set of reagents (DRG, manufactured in Germany). The content of 
nitrogen (II) oxide stable active metabolites S-nitrosothiols was determined by 
fluorimetric method [34].
Experimental animals were administered APFC for 2 weeks (since third week of 
pathology simulation) using a special iron catheter for intragastric administration. 
The dose of APFC was calculated as total content of polyphenols—9 mg/100 g of 
body weight (prophylactic treatment). The dose of reference preparation EGCG 
(produced by Sigma-Aldrich, Germany) was 3 mg/100 g of body weight. Daily ani-
mal equivalent doses (AED) were calculated according to the latest recommenda-
tions for preclinical studies, taking into account the average daily dose for humans 
and interspecies difference in body weight and body surface area [13].
The results were statistically processed using the 4Pl statistical logistic method 
with free internet service of MyAssays® and nonparametric analysis methods 
(Mann-Whitney U-Test) with the standard software package STATISTICA 7.0 [14].
2.2.2 Results
Under our experimental conditions, it was observed a significant simultaneous 
increase in glucose and IRI level, which at the IR development initial stages (fifth week 
of experiment) mediated the nitrogen oxide production increase; it was confirmed by 
the nitrate and nitrite evaluation of the (NO-2 + NO-3) content. The last fixed fact was 
caused by the insulin inducing effect on the endothelial cell NO-synthase (iNOS) and 
the arginine flow activation (NOS substrate) into the cells (Table 4). Since citrulline is 
the another product of the NO-synthase reaction in addition to nitrogen (II) oxide, in 
our experiments, growth of this indicator was observed, which directly correlated with 
the increase in the content of NO-2 + NO-3 (Table 4).
According to the other studies in in vivo experiments, it has shown that insulin 
in physiological concentrations mediates NO-dependent vasodilation, which is 
accompanied by blood pressure normalization. The insulin vasoprotective action 
is based on the phosphatidylinositol-3-kinase activation in endothelial cells and 
microvessels. It leads to the endothelial NOS gene expression and insulin-mediated 
vasodilatation.
Hyperglycemia that developed under our experimental conditions led to the 
iNOS expression up-regulation and increased ROS production with free radical 
processes activation. Simultaneous increase in the nitrogen oxide and ROS con-
tent resulted in the peroxynitrite formation and significantly contributed in ED 
pathogenesis. The synchronous free radical formation under hyperglycemia caused 
damage to protein and lipid cell structures, which led to the highly toxic lipoperoxide 
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compound formation that enhanced the cell membrane destabilization. These patho-
logical changes are accompanied by antioxidant defense dysfunction, which resulted 
in cell energy homeostasis disorders due to the tricarboxylic acid cycle suppressing 
and uncoupling of tissue respiration and oxidative phosphorylation. Furthermore, 
NO hyperproduction stimulated COX-2 expression, which in turn was accompanied 
by the vasoconstrictor factor formation intensification (thromboxane A2, an antago-
nist of NO). The combination of these factors creates preconditions for endothelium 
damage and the ED progression.
It is known that prolonged hyperglycemia stimulates the polyol pathway of 
glucose metabolism, leading to the depletion of glutathione reserves (potent 
antioxidant factor) and endothelial NOS-NADPH(H+) cofactor in endothelial 
cells. The conditions of lasting hyperglycemia cause eNOS activity inhibition and, 
as a result, a decrease in the nitric oxide formation [35]. The above changes are 
corrected by increasing of diacylglycerol and protein kinase C activity. Literature 
data analysis indicates the prominent role of chronic hyperglycemia as a factor of 
the vascular complications pathogenesis under the treatment of IR and associated 
diseases, primarily angiopathy under diabetes mellitus. Lasting hyperglycemia is 
accompanied by the increase in the content of glycosylated hemoglobin and other 
end products of glycosylation. The last ones significantly reduce the availability of 
nitrogen (II) oxide, which is an important factor in endothelial function disorders. 
Hyperglycemia induces an increase in the lipid peroxidation products content that 
suppress the endothelium ability to vasodilatation [36].
At the tenth week of the experiment, under the lasting IR, we observed a 
significant increase in the endothelin (ET-1) content (in 2.58 times), while the con-
centration of stable NO metabolites (S-NO) was significantly lower (in 3.26 times) 
compared with indices in healthy animals. The ED development was confirmed by 
the calculation of the ET-1/S-NO ratio, which was 8.4 times higher in animals with 
IR than the similar index in healthy animals (Table 5).
ET-1 has a prognostic importance for cardiovascular pathologies. This vaso-
constrictor factor is a marker of coronary atherosclerosis and coronary ED. The 
results of other authors’ studies indicate a significant role of abdominal adiposity in 
increasing of the ET-1 production, which evidences about increased vasoconstrictor 
factors production under MS. The ET-1 content directly correlates with the average 
blood pressure. This marker is considered as an independent factor in the develop-
ment and arterial hypertension progression in patients with obesity and MS [37].
2.2.3 Discussion
Under the conditions of experimental IR, the ED formation occurs gradually 
with the several pathological mechanisms involvement. On the one hand, there are 
disorders in the NO-synthase system functional activity. On the other hand, there 
is a marked imbalance of antioxidant-prooxidant factors in the direction of prooxi-
dants content increasing.
According to some researchers, under the IR in the endothelium is stimulated 
the vasoconstrictor substances synthesis (ET-1, thromboxane A2, prostaglandin 
F2) and reduced the vasodilator production (prostacyclin and nitric oxide). Lasting 
IR syndrome is accompanied by a decrease in endothelial- and insulin-mediated 
vasodilation. The activation of the MAPK-passway by insulin via stimulation of the 
different growth factors is an important aspect of the pathogenesis of vessel damage 
caused by insulin under IR. Thus MAPK activation leads to stimulation of prolifera-
tive processes and the smooth muscle cell migration, strengthening of vascular 
remodeling, and proatherogenic changes. It is believed that one of the points of the 
arterial hypertension pathogenesis under MS is the ability of insulin to promote 
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hypertrophy of smooth muscle vessels. Under IR, the endothelium becomes a target 
for a number of damaging factors (oxidized LDL, free radicals, etc.), which is 
accompanied by disorders in the endothelium functional state and creates the basis 
for the cardiovascular complication development [38].
Our previous studies, which correspond with literature data, indicated that 
experimental IR is accompanied with proatherogenic changes in the blood pro-
file, and the ET-1 index increase is a marker of hypoxic state that is specific to 
atherogenesis. Oxidatively modified very low-density lipoproteins (VLDL) are 
some from the ET-1 synthesis inductors [31]. Thus, under the conditions of our 
experiments, the ED formation was evident; it was confirmed by the correspond-
ing changes in the studied parameters. These change dynamics proved proathero-
genic disorders that took place under this modeled pathology. In general, the ED 
development mediated by atherogenesis is a main factor in the CVD complication 
pathogenesis, which caused high mortality rates.
The tested APFC administration to animals deeply corrected the pathologi-
cal changes that are accompanied by the ED formation at different stages of the 
experimental IR development. This fact was proved by significant positive changes 
and normalization of the endothelium function marker content.
Under the action of food concentrate in animals, which were injected by dexa-
methasone for 5 weeks and fed with a high-calorie diet, the nitrate/nitrite and 
citrulline contents were reduced to almost healthy animals’ levels. Naturally, there 
was a significant increase in arginine level that was not used as intensively as the 
substrate for NOS (as was in the case with animals of model pathology).
The above changes are the result of the complex APFC component therapeu-
tic effects. The antioxidant-prooxidative balance was shifted, and free radical 
processes were activated under the IR. The formation of ED under lasting IR state 
was mediated by the induction of NADPH(H+) oxidase endothelial expression, in 
which induction correlates with the high superoxide anion production. It, in turn, 
reduces the nitrogen oxide bioavailability and its stable metabolite content, which 
occurred in the conditions of our experiments (Table 5). The APFC administra-
tion to rats prevents these changes: the S-NO content significantly increased while 
the vasoconstrictor ET-1 level and their ratio were decreased. The possible mecha-
nism can involve both direct antioxidant activity of phenolic compounds and 
suppressing of the NADPH(H+)-oxidase expression, which plays a prominent role 
in the oxidative stress development in the endothelium. The ability of phenolic 
compounds in red wine and green tea to suppress the expression of NADPH(H+)-
oxidase subunits (in particular, p22phox and nox1) and, respectively, to inhibit 
the endothelial production of superoxide anion was proved [39]. Polyphenols are 
also characterized by an increase in catalase activity. Phenolic compounds, due 
to the phosphoinositol pathway initiation, stimulate the NO production and the 
endothelial hyperpolarizing factor. Taking into account the chemical composition 
of these substances and the APFC are similar, it is possible that their mechanisms 
for the realization of biological activity, in particular vasoprotective action, can 
be equivalent.
The concentrate contains the highest quantity of gallic acid, which mediates 
a variety of biological effects. According to literary data, gallic acid has powerful 
anti-inflammatory properties, which are mediated by several mechanisms. It has 
been demonstrated that gallic acid and its esters (gallates) have ability to inhibit 
NF-κB activation, mainly due to suppression of IL-1 and tumor necrosis factor 
(TNF) (including endothelial cells) production. Thus, gallic acid and its derivatives 
are capable of inhibiting the cytokine-induced nuclear translocation of NF-κB. It 
is assumed that galactic acid blocks the activation of the NF-κB and Akt signal-
ing pathway through the suppression of COX and ribonucleotide reductase (It is 
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associated with the presence of anticarcinogenic properties). Some studies have 
shown the gallic acid antagonism against P-selectin, which, as known, mediate the 
blood-formed element adhesion, in particular, leukocytes and monocytes, to the 
endothelium, which is accompanied by the inflammation progression. Considering 
the fact that the inflammatory reaction in the endothelium is one of the main 
components in the ED formation, inhibition of this process prevents the disorders 
in its functional activity. Gallic acid reduces the secretion of monocyte chemotaxis 
protein 1 (MCP-1), intercellular adhesion molecule 1 (ICAM-1), and vascular 
endothelial adhesion molecule 1 (VCAM-1) in endothelial cells [40].
The therapeutic effect on hyperglycemia and hyperinsulinemia mediated the 
peroxynitrite production suppression (specific to quercetin), which was resulted in 
the NO-synthase system improvement (at the initial stages of the model pathology 
development) [41].
Long-term quercetin and its metabolites supplementation, which are con-
tained in the studied concentrate, caused AMPK and eNOS activation (probably 
via increasing phosphorylation) in endothelium cells. This activation leads to an 
increase in the S-NO concentration that was observed in the conditions of our 
experiments (Table 5). In this case, quercetin was able to reduce the content of 
ET-1, which was also determined in our experiments (Table 5), and it was corre-
sponded with the literature data. It is supposed that quercetin reduces H2O2-induced 
expression of the mRNA of ET-1, and thus, it reduced ED severity mediated by 
ET-1 hyperproduction. In addition, quercetin reduces the p47phox subunit of 
NADPN(H+)-oxidase expression by protein kinase C inhibition, which is resulted 
in an oxidative stress reduction. Quercetin supplementation leads to a decrease in 
platelet excessive aggregation, which leads to atherosclerosis complications and 
stenotic arteries embolism. According to the literature, quercetin exhibits distinct 
anti-inflammatory effects, reducing the activation of NF-κB, TNF-α, IL-1β, IL-6, 
and SRP. It is known that anti-inflammatory properties of quercetin are improved 
by ascorbic acid (the studied concentrate contains both components that suggested 
more pronounced anti-inflammatory effect) [21, 22].
Long-term supplementation of caffeic, chlorogenic, and ursolic acids exhibits a 
potent antioxidant effect and increases the nitrogen oxide bioavailability, which was 
proved by S-NO increase in our experiments. According to the other authors, chlo-
rogenic acid is characterized by ability to decrease in the malondialdehyde content 
in LDL, which is evidenced about their stability against oxidative modification and, 
accordingly, prevention of proatherogenic changes [42].
The EGCG administration also improved the pathological changes in the 
endothelium functional state, mediated by the experimental IR, but this effect 
was less pronounced at all stages of the model pathology development than the 
effect of APFC. It should be noted that at the experimental IR initial stage (fifth 
week of the experiment), the effect on nitrates and nitrites level, arginine, and 
citrulline content under EGCG administration was significantly less compared 
with the results determined in the group of animals that administered the food 
concentrate.
Thus, the APFC administration prevented ED formation under experimental 
IR. We suppose that this effect was mediated by the complex synergistic effect of 
its constituent components including a potent antioxidant effect and abilities to 
modulate the activity of nitric oxide synthase and suppress the ET-1production, 
resulting in a vasoprotective effect. The EGCG administration was also accompa-
nied by an improvement of the endothelium functional state under experimental 
pathology; however, the EGCG therapeutic effect was less pronounced compared 
with complex compound—the APFC, due to multivector effects on different parts 
of the ED formation.
Antioxidants
12
3.  The study of the blueberry (Vaccinium myrtillus L.) extract effectiveness 
under experimental diabetes mellitus induced by a high-fructose diet 
combined with dexamethasone injections
3.1 Materials and methods
DM2 is an endocrine disorder characterized by defects in mechanism of glucose 
insulin-mediated transport into the cells, resulting in persistent hyperglycemia. It 
is well known that glucose high levels lead to the free radical overformation, which 
activates lipoperoxidation—one of the main pathogenetic factors in atherosclerosis 
development [3, 4].
Bilberry leaf chemical composition usually consists of flavonoids, proantho-
cyanidins, triterpenes, and also phenolic compounds, in particular, of myricetin, 
which revealed an effectiveness at the DM2 initial stages of according to some 
authors [43, 44].
The experiment was conducted on male Wistar rats weighing 160–200 g. The 
experimental animals were divided into groups: (1) intact animals fed a standard 
vivarium chow; (2) animals fed a high-fructose diet (2 g of fructose/100 g of body 
weight daily) combined with daily subcutaneous dexamethasone injections in the 
dose of 2 mg/100 g body weight for 6 weeks; and (3) animals, which administered 
intragastric feeding of bilberry leaf dry extract in the dose of 9 mg/100 g of body 
weight for 2 weeks in addition to dexamethasone administration [45].
The glycosylated hemoglobin (HbA1C) concentration was determined in blood 
serum by immunoturbidimetric method. The fructosamine level was measured by 
the spectrophotometric method using nitro-blue tetrazolium chloride [46]. The area 
under the glycemic curves (AUC) during IGGTT was calculated using the com-
puter software program MATLAB [47]. The glucose content was determined using 
standard kit of “Filisit-Diagnostika” (Ukraine). The basal level of immunoreactive 
insulin (IRI) was measured in the blood of animals by the in vitro radioimmunoassay 
using a standard set of reagents produced by “Immundiagnostik” (Germany) [10].
The lipoperoxidation markers were determined spectrophotometrically by the 
measuring of diene conjugates (DC) and TBA-reactive products (TBA-RP) content 
using reaction with thiobarbituric acid [48]. The antioxidant system status was 
evaluated via determination of reduced glutathione (GSH) concentration (spectro-
photometrically by reaction with alloxan) and glutathione reductase (GR) activity 
[49]. Glucose homeostasis in test and control animals was evaluated at different 
times after the model inducing (7, 14, and 21 days) by basal glycemic indexes and 
intraperitoneal glucose tolerance test (IPGTT, 3 g/kg body weight) [50]. Statistical 
processing of the experimental data was performed using the STATISTICA software 
program (StatSoft Inc., USA, version 6.0). The significance of intergroup differences 
was estimated according to the Student’s t-test [14].
3.2 Results and discussion
The dexamethasone low dose administration to laboratory animals under high-
fat diet caused the multiple disorder formation specific to MS and DT2. In the rats’ 
blood serum, there was a significant increase in the glycosylated hemoglobin level, 
fructosamine concentration, glucose content, basal glycemia, and increased area 
under glycemic curves. These changes were probably developed due to a decrease 
in the glucose utilization by peripheral tissues caused by inhibition of the glucose 
transporters expression (GLUT1 and GLUT4) under the influence of dexametha-
sone action. Change in HbA1C level is an objective indicator of carbohydrate metab-
olism in diabetic patients and the effectiveness of glycemic control. An increase in 
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the content of glycosylated hemoglobin is usually considered as an indirect marker 
for the retinopathy development, nephropathy, and other complications of diabe-
tes. Due to the long-term hyperglycemia, albumin was subjected to nonenzymatic 
glycosylation, which was confirmed by the increase in fructosamine in our experi-
ments (Table 6). The dry bilberry leaf extract (BLE) administration under model 
pathology was accompanied by a significant normalization of the studied indices 
(Tables 6 and 7).
In particular, it was significant for the suppression of glycosylated hemoglobin 
(by 12.5%) and fructosamine (by 32%) concentration, hyperglycemia (by 26.8%), 
the area under the glycemic curves (by 47.4%), and the immunoreactive insulin 
level (by 5.1%) compared to untreated animals. In our opinion, it is due to the 
high content of different phenolic compounds in the bilberry extract, which have 
hypoglycemic and antioxidant effects. The mechanism of hypoglycemic effect of 
polyphenols is related to their impact on the process of glucose transport into the 
cell. The main role in hypoglycemic action of the extract of bilberry leaves belongs 
to myrtilline, which is a mixture of delphinidin and malvinidin esters that act as 
insulin synthesis activator [51].
It is proved that hyperglycemia is accompanied by free radical processes activa-
tion, which leads to complications in the main disease pathogenesis and tissue 
damage. Under the conditions of our experiments, the model pathology formation 
Parameters Intact control Model pathology BLE + model 
pathology
Glycosylated hemoglobin (%) 7.5 ± 0.5 9.6 ± 0.7* 8.4 ± 0.6*,#
Fructosamine (mmol/l) 1.91 ± 0.12 3.6 ± 0.29* 2.45 ± 0.24*,#
Basal blood glucose level (mmol/l) 4.04 ± 0.11 13.42 ± 0.38* 12.08 ± 0.24*
AUC (glycemic) (mmol/l/min) 625.44 ± 16.56 2092.25 ± 60.48* 1100 ± 61.56*,#
Glucose, mmol/l 4.6 ± 0.1 11.2 ± 0.2* 8.2 ± 0.1*,#
ІRІ (pmol/l) 221.74 ± 20.79 317.97 ± 39.72* 302 ± 36.70*
n, number of animals in a group.*Variation is statistically significant in comparison with intact control group indices 
(р ≤ 0.05).
#Variation is statistically significant in comparison with model pathology group indices (р ≤ 0.05).
Table 6. 
The effect of bilberry leaf extract on carbohydrate metabolism indices under experimental diabetes mellitus 
induced by high-fructose high-calorie diet combined with dexamethasone injection, n = 10.
Parameters Intact control Model pathology BLE + model 
pathology
TBA-AP (nmol/g) 0.96 ± 0.27 3.56 ± 0.41* 0.98 ± 0.39#
DC (nmol/l) 22.30 ± 1.42 28.5 ± 0.94* 26.9 ± 0.96
GSH (mmol/g) 0.25 ± 0.01 0.12 ± 0.02* 0.19 ± 0.03
GR (nmol/min mg) of protein 18.56 ± 0.64 14.20 ± 1.06* 17.9 ± 0.98
n, number of animals in a group.*Variation is statistically significant in comparison with intact control group indices 
(р ≤ 0.05).
#Variation is statistically significant in comparison with model pathology group indices (р ≤ 0.05).
Table 7. 
The effect of bilberry leaf extract on the specific markers of antioxidative-prooxidative status of rat’s liver 
in experimental diabetes mellitus induced by high-fructose high-calorie diet combined with dexamethasone 
injection, n = 10.
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was accompanied by the oxidative stress development, which was confirmed by 
significant increase in the content of TBA-AP and DC (basic lipoperoxidation prod-
ucts) in the liver—by 270.8 and 27.8%, respectively, compared with healthy rats. 
At the same time, antioxidant defense was reduced as evidenced by the decrease in 
the content of GSH and GR in the liver by 52 and 23.5%, respectively, compared to 
intact control animals. The above changes confirmed the oxidative stress develop-
ment under pathology. The BLE administration under the model pathology led to 
the antioxidative-prooxidative balance normalization, which was evidenced by the 
significant suppression of lipoperoxidation and antioxidant status improvement, 
which was reflected in the relevant indicator dynamics. We suggested that these 
changes were the result of remarkable antioxidant and antiradical properties of the 
investigated extract components.
Thus, the effectiveness of the BLE under the experimental DT2 primary was due 
to the expressive antioxidant properties of the biologically active substances that are 
part of its composition.
4. Conclusions
Summarizing the above, the results of these and other experiments demonstrate 
that natural antioxidants of polyphenolic structure have a significant corrective 
effect on major factors in the pathogenesis of obesity. Firstly, polyphenolic anti-
oxidants promote lipid and carbohydrate metabolism, which is very important 
for directional therapy of obesity. In the other hand, these compounds prevent 
comorbid conditions of obesity, such as endothelial dysfunction and atherosclero-
sis, which greatly increases the risk of mortality. Also, polyphenolic antioxidants 
reverse insulin resistance and its after-effects linked with oxidative tissue damage. 
The main explanation of such protective effects of natural polyphenolic compounds 
is based on their powerful antioxidative properties, because the pathogenesis of 
noted disorders is usually amplified by exponential releasing reactive oxygen spe-
cies and their products. Consequently, the pool of current experimental data points 
out that concentrates of polyphenolic compounds could be used in adjuvant therapy 
of obesity, diabetes, and similar conditions, complicated by metabolic disorders and 
free radical oxidation.
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